



Millendo Therapeutics to Participate in Upcoming Investor Conferences

ANN ARBOR, Mich., August 10, 2018 – [Millendo Therapeutics, Inc.](http://www.millendo.com), a clinical-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases, today announced that Julia C. Owens, Ph.D., President and Chief Executive Officer, will participate in the following August conferences:

- 2018 Oppenheimer Newport Summit for Revolutionary Biotechnology on Monday, August 13, 2018 in Newport, RI, where the Company will host investor meetings
- 2018 Wedbush PacGrow Healthcare Conference, where the Company will provide a corporate overview and pipeline update on Wednesday, August 15, 2018 at 9:45 AM ET in New York, NY

About Millendo Therapeutics, Inc.

Millendo Therapeutics is focused on developing novel treatments for orphan endocrine diseases. The Company's objective is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. The Company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing's syndrome. For more information, please visit www.millendo.com.

###

Media Contact:

Cammy Duong
MacDougall Biomedical Communications
781-591-3443
cduong@macbiocom.com

Investor Contact:

Stephen Rutman
Stern Investor Relations
212-362-1200
stephen@sternir.com